Lupin erhält Zulassung in China für Oseltamivirphosphat-Suspension zum Einnehmen

Lupin Limited announced that the National Medical Products Administration of China has approved the abbreviated registration application for Oseltamivir Phosphate, which Lupin submitted in partnership with Yabao Pharmaceuticals, a leading company in the Chinese pediatric market. This marks Lupin's debut product in the Chinese market, representing a significant milestone in the company's global expansion.

The Oseltamivir Phosphate oral suspension, 6 mg/ml, will be introduced and marketed to increase accessibility, particularly for pediatric use. This move further expands Lupin's global presence and reaffirms its commitment to providing high-quality and affordable medications to patients and children in need.

The Oseltamivir Phosphate oral suspension, 6 mg (Base)/ml, is indicated for:

• The treatment of Influenza A and B in patients aged 2 weeks and older
• The prophylaxis of Influenza A and B in individuals aged 1 year and older

Fabrice Egros, Head of Corporate Development at Lupin, stated, "We are very pleased to have received approval for the Oseltamivir Oral Suspension in China. This is a strategic step for our entry into one of the largest pharmaceutical markets in the world. It reflects our shared commitment to expanding access to high-quality, affordable therapies, especially in pediatric care. We look forward to building a stronger presence in this market through our partnership."

Wei Ren, President of Yabao, commented, "We are excited to announce the official approval of the Oseltamivir Oral Suspension in China. It marks an important milestone in our partnership with Lupin. This underscores Yabao's commitment to high-quality pediatric medicines and demonstrates our strong collaboration. We will continue to expand our R&D portfolio for medications treating chronic diseases in children and adults to advance our business together."

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in various pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin has established a strong position in India and the United States in several therapeutic areas, such as respiratory diseases, cardiovascular conditions, diabetes, infectious diseases, gastrointestinal disorders, central nervous system issues, and women's health. The company operates 15 state-of-the-art manufacturing facilities and 7 research centers worldwide, employing approximately 24,000 dedicated personnel.